Trial Profile
An analysis on distribution and inter-relationships of biomarkers under edoxaban in Japanese patients with non-valvular atrial fibrillation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Jun 2020
Price :
$35
*
At a glance
- Drugs Edoxaban (Primary)
- Indications Embolism and thrombosis; Stroke
- Focus Biomarker; Pharmacodynamics; Pharmacokinetics
- Acronyms CVI ARO 7 study
- Sponsors Daiichi Sankyo Company
- 28 Jul 2017 New trial record